Services

IgA ASGPR Clearance Evasion Service

Background Service Advantages Applications FAQs

Reducing Hepatic Elimination of IgA via Targeted Glycoengineering

Rapid clearance of glycoproteins through the asialoglycoprotein receptor (ASGPR) pathway remains a key limitation for recombinant IgA molecules, particularly those lacking terminal sialic acid residues. Our IgA ASGPR Clearance Evasion Service focuses on precise glycan remodeling strategies to shield terminal galactose residues, thus minimizing hepatic uptake and enhancing IgA persistence in circulation.

Through an integrated approach combining glycosylation optimization, cell line modification, and glycoform selection, Creative Biolabs delivers tailor-made IgA antibodies with reduced affinity to ASGPR without impairing antigen specificity or polymeric assembly.

Service Highlights

Glycan Remodeling to Mask Galactose

Enzymatic addition of sialic acid or fucose residues to block exposed galactose moieties on N-glycans, reducing ASGPR-mediated recognition.
Optional glycan trimming (via galactosidase or glycosidase) to standardize precursor structures for efficient shielding.

ASGPR Binding Assays & Affinity Profiling

In-house ASGPR binding ELISAs, SPR, and cell-based clearance models to measure relative uptake and receptor interaction kinetics.
Comparison with native and sialylated control IgA molecules.

Cell Line-Based Glycoengineering

Stable overexpression of sialyltransferases and fucosyltransferases in CHO/HEK cells to produce ASGPR-evasive glycoforms in upstream processing.
Support for custom host cell engineering based on your IgA backbone requirements.

Comprehensive Biochemical Validation

Confirmed glycan profiles using mass spectrometry, 2-AB labeling, and lectin panel binding.
FcαRI and pIgR binding tested to validate retention of core IgA effector functions.

Advantages of Our Service

Reduced Hepatic Clearance: Engineered glycan structures minimize ASGPR interaction, enabling longer systemic persistence.
Preserved Effector Function: Our strategy does not alter antigen-binding or FcαRI-mediated immune activation.
Platform-Ready: Applicable to full-length, bispecific, or IgA-IgG hybrid formats.
Data-Rich Validation: All constructs are fully profiled for glycan structure, ASGPR affinity, and biophysical behavior.

Applications

Fig.1 Applications of this service. (Creative Biolabs Original)

FAQs

Q1: What is the primary structure ASGPR recognizes?

A1: ASGPR binds terminal galactose and N-acetylgalactosamine residues. Blocking or capping these sites with sialic acid or fucose can effectively evade recognition.

Q2: How is ASGPR interaction measured?

A2: We use lectin competition studies and label-free kinetics platforms (e.g., SPR) to quantify receptor affinity.

Q3: Will this interfere with IgA polymerization or mucosal transport?

A3: No. Our workflow preserves the J-chain and pIgR-binding domains, ensuring natural polymeric behavior and mucosal delivery capacity.

Q4: Can you deliver constructs with varying levels of ASGPR evasion?

A4: Yes, we can create titrated glycoform series to help evaluate optimal ASGPR interaction levels for your intended use.

Contact Us

At Creative Biolabs, we are committed to advancing IgA antibody engineering with precision glycoediting strategies tailored to your research and development goals. If you are exploring ways to reduce hepatic clearance through ASGPR pathway modulation or require support in customizing IgA glycoforms for enhanced stability and circulation, our scientific team is here to assist.

For more information about our IgA ASGPR Clearance Evasion Service, or to request a quote or technical consultation, please contact us.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.